-- Melanoma Pipeline Market Companies Involved in Therapeutics Development are 4SC AG ,AB Science SA ,AbbVie Inc. ,ACF Pharmaceuticals, LLC ,Adamis Pharmaceuticals Corporation ,Adaptimmune Therapeutics Plc ,Adicet Bio, Inc. ,Aduro BioTech, Inc. ,Advaxis, Inc. ,Aeterna Zentaris Inc. ,Affichem SA ,Agalimmune Ltd ,Agenus, Inc. ,Agilvax, Inc. ,AGV Discovery, SAS ,AIMM Therapeutics B.V. ,Alethia Biotherapeutics Inc. ,Altor BioScience Corporation ,Amgen Inc. ,Anavex Life Sciences Corp. ,Angimmune LLC ,Antibe Therapeutics, Inc. ,Antigen Express, Inc. ,APEIRON Biologics AG ,Apexigen, Inc. ,Aphios Corporation ,APO-T B.V. ,Apogenix GmbH ,Aposense Ltd. ,Aptose Biosciences Inc. ,Arisaph Pharmaceuticals, Inc. ,Array BioPharma Inc. ,Asana BioSciences, LLC ,Astex Pharmaceuticals, Inc. ,AstraZeneca Plc ,Aurigene Discovery Technologies Limited ,Azaya Therapeutics, Inc. ,Basilea Pharmaceutica AG ,Batu Biologics, Inc. ,Bayer AG ,BeiGene, Ltd. ,Beijing Kawin Technology Share-Holding Co., Ltd. ,Bellicum Pharmaceuticals, Inc. ,Bio-Cancer Treatment International Limited ,BioApex, s.r.o. ,BIOCAD ,Biogazelle ,Biogenomics Limited ,BioLineRx, Ltd. ,Bioncotech Therapeutics S.L. ,Bionomics Limited ,BioNTech AG ,Bioo Therapeutics ,Biovista Inc. ,Boehringer Ingelheim GmbH ,Boston Biomedical, Inc. ,Bristol-Myers Squibb Company ,Calithera Biosciences, Inc. ,Can-Fite BioPharma Ltd. ,CCRP Therapeutics GmbH ,Cellceutix Corporation ,Celldex Therapeutics, Inc. ,Celprogen, Inc. ,Celyad SA ,Chipscreen Biosciences Ltd ,Cipher Pharmaceuticals Inc. ,Cornerstone Pharmaceuticals, Inc. ,Cortice Biosciences, Inc. ,Corvus Pharmaceuticals, Inc. ,Cytune Pharma SAS ,CyTuVax B.V. ,CZ BioMed Corp ,Daiichi Sankyo Company, Limited ,Deciphera Pharmaceuticals, LLC ,Delcath Systems, Inc. ,Dicerna Pharmaceuticals, Inc. ,Digna Biotech, S.L. ,DormaTarg, Inc. ,Dynavax Technologies Corporation ,Eisai Co., Ltd. ,Eli Lilly and Company ,Elsalys Biotech SAS ,Ensol Biosciences Inc. ,EntreChem, S.L. ,Erytech Pharma SA ,eTheRNA Immunotherapies NV ,Exelixis, Inc. ,F. Hoffmann-La Roche Ltd. ,Faes Farma, S.A. ,FirstString Research, Inc. ,Five Prime Therapeutics, Inc. ,Formune S.L. ,Galapagos NV ,Galectin Therapeutics, Inc. ,Genelux Corporation ,Genzyme Corporation ,GlaxoSmithKline Plc ,Gradalis Inc. ,GreenPeptide Co., Ltd. ,Hadasit Medical Research Services & Development Ltd ,Hanmi Pharmaceuticals, Co. Ltd. ,Heat Biologics, Inc. ,HEC Pharm Co., Ltd. ,Histogen, Inc. ,Horizon Pharma Plc ,Idera Pharmaceuticals, Inc. ,Ignyta, Inc. ,Immodulon Therapeutics Ltd. ,Immune Design Corp. ,Immune Response BioPharma, Inc. ,ImmunGene, Inc. ,Immunocore Limited ,ImmunoFrontier, Inc. ,ImmunoGen, Inc. ,Immunomic Therapeutics, Inc. ,Immupharma Plc ,ImmuRx, Inc. ,IMPACT Therapeutics, Inc. ,Imugene Limited ,Incuron, LLC ,Incyte Corporation ,Infinity Pharmaceuticals, Inc. ,Inovio Pharmaceuticals, Inc. ,InteRNA Technologies B.V. ,IO Biotech ApS ,JHL Biotech, Inc. ,Jiangsu Hengrui Medicine Co., Ltd. ,KaloBios Pharmaceuticals, Inc. ,Kancera AB ,Karyopharm Therapeutics, Inc. ,Kite Pharma, Inc. ,Kolltan Pharmaceuticals, Inc. ,Kura Oncology, Inc. ,Kuros Biosciences AG ,Life Science Pharmaceuticals, Incorporated ,Lindis Biotech GmbH ,Lipotek Pty Ltd. ,Loxo Oncology, Inc. ,Luitpold Pharmaceuticals, Inc. ,Lytix Biopharma AS ,MacroGenics, Inc. ,Magnus Life Science ,MaxiVAX SA ,MediaPharma s.r.l. ,MedImmune, LLC ,Medisyn Technologies, Inc. ,Medivation, Inc. ,MELEMA Pharma GmbH ,Merck & Co., Inc. ,Merck KGaA ,Millennium Pharmaceuticals, Inc. ,Mirna Therapeutics, Inc. ,Modulate Therapeutics, Inc. ,Molecular Templates Inc. ,Mologen AG ,Morphotek, Inc. ,Nektar Therapeutics ,Nerviano Medical Sciences S.r.l. ,Neumedicines Inc. ,NewLink Genetics Corporation ,NormOxys, Inc. ,Northwest Biotherapeutics, Inc. ,Novartis AG ,Novogen Limited ,Omeros Corporation ,Oncology Research International Limited ,Oncolys BioPharma Inc. ,Oncolytics Biotech Inc. ,OncoNOx ApS ,OncoSec Medical Incorporated ,OncoTartis, Inc. ,Oncovir, Inc. ,Onxeo SA ,OPKO Health, Inc. ,Pacific Northwest Biotechnology, LLC ,PepTx, Inc. ,Pfizer Inc. ,Pharmicell Co., Ltd. ,Pharminox Limited ,Pharmis Biofarmaceutica, Lda. ,Philogen S.p.A. ,PinCell srl ,Pivotal BioSciences, Inc. ,Plexxikon Inc. ,Polaris Pharmaceuticals, Inc. ,Prima BioMed Ltd. ,Provectus Biopharmaceuticals, Inc. ,Provenance Biopharmaceuticals Corp. ,Qu Biologics Inc. ,Reata Pharmaceuticals, Inc. ,Recepta Biopharma S.A. ,Recombio S.L ,Rexahn Pharmaceuticals, Inc. ,Rgenix, Inc. ,Rigontec GmbH ,RXi Pharmaceuticals Corporation ,Sapvax ,Satt Nord SAS ,Scancell Holdings Plc ,Sillajen Biotherapeutics ,SK Biopharmaceuticals Co., Ltd. ,Sorrento Therapeutics, Inc. ,Sumitomo Dainippon Pharma Co., Ltd. ,Sun Pharma Advanced Research Company Ltd. ,Susavion Biosciences, Inc. ,SuviCa Inc. ,Syndax Pharmaceuticals, Inc. ,Synta Pharmaceuticals Corp. ,Taiga Biotechnologies, Inc. ,TaiRx, Inc. ,Taiwan Liposome Company, Ltd. ,Takara Bio Inc. ,Takeda Pharmaceutical Company Limited ,Takis S.r.l. ,Targovax AS ,TC BioPharm Limited ,TetraLogic Pharmaceuticals ,Teva Pharmaceutical Industries Ltd. ,Theravectys SA ,Theryte Limited ,Tikcro Technologies, Ltd. ,Tiltan Pharma Ltd. ,Tocagen Inc. ,TREAT U, S.A. ,TVAX Biomedical, Inc. ,TyrNovo Ltd. ,UbiVac, LLC ,Ultimovacs AS ,UNC Health Care ,Vaccibody AS ,Vascular Biogenics Ltd. ,Vault Pharma Inc. ,Vichem Chemie Research Ltd. ,ViiV Healthcare Limited ,Viralytics Ltd. ,ViraTherapeutics GmbH ,Virttu Biologics Limited ,WntResearch AB ,ZIOPHARM Oncology, Inc.
The report provides comprehensive information on the therapeutics under development for Melanoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Melanoma and features dormant and discontinued projects.
Inquire more about this research at http://www.rnrmarketresearch.com/contacts/inquire-before-buying?rname=655388
Scope
- The report provides a snapshot of the global therapeutic landscape of Melanoma
- The report reviews pipeline therapeutics for Melanoma by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Melanoma therapeutics and enlists all their major and minor projects
- The report assesses Melanoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Melanoma
Complete research report of 1479 Pages with TOC is available at http://www.rnrmarketresearch.com/melanoma-pipeline-review-h1-2016-market-report.html
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Melanoma
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Melanoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Contact Info:
Name: Ritesh Tiwari
Email: Send Email
Organization: RnR Market Research
Address: UNIT no 802, Tower no. 7, SEZ Magarpatta city, Hadapsar Pune, Maharashtra 411013, India
Phone: +1888 391 54 41
Website: http://www.rnrmarketresearch.com/
Release ID: 126906
Google
RSS